A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...
VigenCell, a company specializing in immune cell therapy, is moving toward early commercialization after presenting significant results in Phase 2 ...
A 73-year-old male with a history of relapsed/refractory NK T-cell lymphoma, s/p chemo and immune checkpoint inhibitors therapy. The patient now presents with new onset nephrotic syndrome and acute ...
Company’s first clinical trial studying CAR-NK (CD19 t-haNK) cellular therapy in liquid tumors First natural killer cell-based cellular therapy study conducted in the continent of Africa Complete ...
A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...
It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function. The specific treatment course and prognosis for T-cell ...
Nkarta pivots its NK pipeline to autoimmune disease with NKX019 progress and strong cash runway supporting milestones into ...
The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced new data highlighting the quality-of-life ...
A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback